Du är här

2014-05-28

Bavarian Nordic A/S: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/c

KVISTGAARD, Denmark, May 28, 2014
- Pursuant to Section § 28a of the Danish Act on Securities Trading, Bavarian
Nordic A/S reports the following transactions of shares and related
securities of Bavarian Nordic A/S by persons holding managerial
responsibilities and/or persons/companies closely associated with such.

---------------------------------------------------------------------------------
|Name Claus Bræstrup |
|Reason for transaction Member of the Board of Directors of Bavarian Nordic A/S |
|Issuer Bavarian Nordic A/S |
|ID code/ISIN DK0015998017 |
|Description Shares |
|Transaction Subscription (exercise of warrants) |
|Trading date 27 May 2014 |
|Market NASDAQ OMX Copenhagen |
|Number 4,000 |
|Market value (DKK) 456,000.00 |
---------------------------------------------------------------------------------
About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious
diseases. Lead product candidates are PROSTVAC®, an immunotherapy product
candidate for advanced prostate cancer that is the subject of an ongoing
pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox
vaccine candidate in Phase 3 development, which is being developed and
supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. The vaccine is approved in Canada under
the trade name IMVAMUNE and in the European Union under the trade name
IMVANEX®. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under
the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a
sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.
For more information, visitwww.bavarian-nordic.com.

Contacts
Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47
43
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

201414uk
http://hugin.info/100065/R/1788681/614895.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire

HUG#1788681

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.